Minerva Neurosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-293.4M | $1.4M | $-30.0M | $-32.1M | $-49.9M | $1.9M | $-72.2M | $-50.2M |
| Depreciation & Amortization | $5.4K | $5.4K | $5.4K | — | — | $16.0K | $17.5K | $17.5K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.3M | $1.3M | $2.0M | $4.1M | $5.2M | $9.7M | $9.2M | $8.2M |
| Net Cash from Operating Activities | $-13.5M | $-19.6M | $-14.8M | $-24.6M | $-24.6M | $-33.8M | $-43.4M | $-41.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $16.3K | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $0 | $-16.3K | — | $24.5M | $14.1M | $69.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $74.5M | — | $19.6M | $-5 | $60.0M | $13.2M | $525.0K | $-3.3M |
| Net Change in Cash | $60.9M | $-19.6M | $4.8M | $-24.7M | $35.4M | $3.9M | $-28.8M | $24.2M |
| Free Cash Flow | — | — | — | $-24.7M | — | — | — | — |